

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Van Acker et al.

Int'l Appln. No.: PCT/EP2004/052250

Serial No. : Unassigned

Art Unit: Unassigned

Filed : I.A. September 20, 2004

Examiner: Unassigned

For : TIME-OF-ADDITION ASSAY FOR IDENTIFYING ANTI-VIRAL  
COMPOUNDS

MAIL STOP PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

10/570358

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TIP-0062-USPCT/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

\_\_\_\_\_  
Laura A. Donnelly  
Reg. No. 38,435  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1729  
DATED: March 1, 2006

<p align="center"><b>SUBMISSION UNDER MPEP 609 D</b></p> <p align="center">Page 1 of 1</p>	<b>Application Number</b>	Unassigned
	<b>Filing Date</b>	March 1, 2006
	<b>First Named Inventor</b>	Koenraad Lodewijk August Van Acker
	<b>Group Art Unit</b>	Unassigned
	<b>Examiner Name</b>	Unassigned
	<b>Attorney Docket Number</b>	TIP-0062-USPCT

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code <sup>2</sup> (if known)	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
			Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		International Search Report dated January 4, 2005 for related International Application No. PCT/EP2004/052250.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Application Number</b>	Unassigned
<b>Filing Date</b>	March 1, 2006
<b>First Named Inventor</b>	Koenraad Lodewijk August Van Acker
<b>Group Art Unit</b>	Unassigned
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	TIP-0062-USPCT

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>Sheet 2 of 2</p>	Application Number	Unassigned
	Filing Date	March 1, 2006
	First Named Inventor	Koenraad Lodewijk August Van Acker
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	TIP-0062-USPCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Fenard et al., "Secreted phospholipases A <sub>2</sub> , a new class of HIV inhibitors that block virus entry into host cells", Journal of Clinical Investigation, vol. 104, no. 5, pp. 611-618 (1999).	
		Ojwang et al., "T30177, an Oligonucleotide Stabilized by an Intramolecular Guanosine Octet, Is a Potent Inhibitor of Laboratory Strains and Clinical Isolates of Human Immunodeficiency Virus Type 1", Antimicrobial Agents and Chemotherapy, vol. 39, no. 11, pp. 2426-2435 (1995).	
		Nakashima et al., "Anti-Human Immunodeficiency Virus Activity of a Novel Synthetic Peptide, T22 ([Tyr-5,12, Lys-7]Polyphemusin II): a Possible Inhibitor of Virus-Cell Fusion", Antimicrobial Agents and Chemotherapy, vol. 36, no. 6, pp. 1249-1255 (1992).	
		Pannecouque et al., "New Class of HIV Integrase Inhibitors that Block Viral Replication in Cell Culture", Current Biology, vol. 12, no. 14, pp. 1169-1177 (2002).	
		Lin et al., "A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding", Proceedings of the National Academy Sciences of the USA, vol. 100, no. 19, pp. 11013-11018 (2003).	
		Pauwels et al., "Potent and selective inhibition of HIV-1 replication <i>in vitro</i> by a novel series of TIBO derivatives", Nature, vol. 343, no. 6257, pp. 470-474 (1990).	
		Spengler et al., "A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assay That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1", Virology, vol. 280, no. 2, pp. 292-300 (2001).	
		Richman et al., "An adenovirus-based fluorescent reporter vector to identify and isolate HIV-infected cells", Journal of Virological Methods, vol. 99, nos. 1-2, pp. 9-21 (2002).	
		Lee et al., "Generation of the Replication-Competent Human Immunodeficiency Virus Type 1 Which Expresses a Jellyfish Green Fluorescent Protein", Biochemical and Biophysical Research Communications, vol. 233, no. 1, pp. 288-292 (1997).	
		Internet Article 'Online!', "Staccato Cell Station <sup>TM</sup> - Assay", February 2003, pp. 1-2 (XP002271113).	
		Internet Article 'Online!', Automation of Cell-Based Assays", April 2003, pp. 1-4 (XP002271114).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.